We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00606476
First Posted: February 4, 2008
Last Update Posted: November 25, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2012
  Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: October 30, 2013
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):